Drug intelligence / Profile preview

WH010

Development stage: Preclinical
Lead developer: Beijing Wehand-Bio Pharmaceutical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

WH010 is a tumor-targeted nanodrug candidate being developed by Beijing Wehand-Bio Pharmaceutical for the treatment of gastric cancer. The asset is designed as a nanoparticle formulation of a natural product active monomer, a strategy intended to improve the pharmacokinetic profile and tumor-specific delivery of the active compound. By utilizing a targeted delivery mechanism, WH010 aims to maximize anti-tumor activity within gastric malignancies while reducing the potential for off-target systemic toxicities. As of 2024, the specific identity of the natural product monomer and the clinical development phase have not been publicly detailed by the sponsor.

Beyond the preview

Go deeper on WH010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WH010.

Explore the full profile